{"transactions":[{"id":4636444,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T22:06:25.000Z","date":"2026-10-05","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":10.7504,"value":268760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $10.665 to $10.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the \"Issuer\") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2777788,"source":{"system":"sec-edgar","filing":"0001326110-26-000085","document":"wk-form4_1791324382.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000132611026000085/wk-form4_1791324382.xml","form_type":"4"}},{"id":4636440,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32092,"kind":"person","name":"Cohen Cheryl","position":1,"cik":"0001529371","reported_name":"Cohen Cheryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-10-06T22:05:42.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":false,"shares":55979,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":55979,"derivative":{"exercise_price":2.98,"exercise_date":"2023-06-12","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":55979},"source":{"system":"sec-edgar","filing":"0001326110-26-000084","document":"wk-form4_1791324339.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1529371/000132611026000084/wk-form4_1791324339.xml","form_type":"4"}},{"id":4636439,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32092,"kind":"person","name":"Cohen Cheryl","position":1,"cik":"0001529371","reported_name":"Cohen Cheryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T22:05:42.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":81056,"price":10.5,"value":851088.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026."}],"balance_after":100309,"source":{"system":"sec-edgar","filing":"0001326110-26-000084","document":"wk-form4_1791324339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1529371/000132611026000084/wk-form4_1791324339.xml","form_type":"4"}},{"id":4636438,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32092,"kind":"person","name":"Cohen Cheryl","position":1,"cik":"0001529371","reported_name":"Cohen Cheryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T22:05:42.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":true,"shares":55979,"price":2.98,"value":166817.42,"ownership":{"direct":true},"balance_after":181365,"source":{"system":"sec-edgar","filing":"0001326110-26-000084","document":"wk-form4_1791324339.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1529371/000132611026000084/wk-form4_1791324339.xml","form_type":"4"}},{"id":714962,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32092,"kind":"person","name":"Cohen Cheryl","position":1,"cik":"0001529371","reported_name":"Cohen Cheryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-07T00:26:22.000Z","date":"2026-07-02","kind":"exercise","planned":true,"acquired":false,"shares":55979,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":111958,"derivative":{"exercise_price":2.98,"exercise_date":"2023-06-12","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":55979},"source":{"system":"sec-edgar","filing":"0001529371-26-000008","document":"wk-form4_1783383979.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000152937126000008/wk-form4_1783383979.xml","form_type":"4"}},{"id":714961,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32092,"kind":"person","name":"Cohen Cheryl","position":1,"cik":"0001529371","reported_name":"Cohen Cheryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T00:26:22.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":131210,"price":9.5034,"value":1246941.114,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 131,210 shares sold in the price range of $9.50 to $9.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the \"Issuer\") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":125386,"source":{"system":"sec-edgar","filing":"0001529371-26-000008","document":"wk-form4_1783383979.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000152937126000008/wk-form4_1783383979.xml","form_type":"4"}},{"id":714960,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32092,"kind":"person","name":"Cohen Cheryl","position":1,"cik":"0001529371","reported_name":"Cohen Cheryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T00:26:22.000Z","date":"2026-07-02","kind":"exercise","planned":true,"acquired":true,"shares":55979,"price":2.98,"value":166817.42,"ownership":{"direct":true},"balance_after":256596,"source":{"system":"sec-edgar","filing":"0001529371-26-000008","document":"wk-form4_1783383979.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000152937126000008/wk-form4_1783383979.xml","form_type":"4"}},{"id":714956,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-07T00:25:29.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":124414,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.99,"exercise_date":"2024-06-10","expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":124414},"source":{"system":"sec-edgar","filing":"0001849739-26-000014","document":"wk-form4_1783383927.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000014/wk-form4_1783383927.xml","form_type":"4"}},{"id":714955,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-07T00:25:29.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":35064,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.98,"exercise_date":"2023-06-12","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":35064},"source":{"system":"sec-edgar","filing":"0001849739-26-000014","document":"wk-form4_1783383927.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000014/wk-form4_1783383927.xml","form_type":"4"}},{"id":714954,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T00:25:29.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":159478,"price":9.0236,"value":1439065.6808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the \"Issuer\") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001849739-26-000014","document":"wk-form4_1783383927.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000014/wk-form4_1783383927.xml","form_type":"4"}},{"id":714953,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T00:25:29.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":124414,"price":2.99,"value":371997.86,"ownership":{"direct":true},"balance_after":159478,"source":{"system":"sec-edgar","filing":"0001849739-26-000014","document":"wk-form4_1783383927.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000014/wk-form4_1783383927.xml","form_type":"4"}},{"id":714952,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T00:25:29.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":35064,"price":2.98,"value":104490.72,"ownership":{"direct":true},"balance_after":35064,"source":{"system":"sec-edgar","filing":"0001849739-26-000014","document":"wk-form4_1783383927.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000014/wk-form4_1783383927.xml","form_type":"4"}},{"id":720975,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":124414,"derivative":{"exercise_price":2.99,"exercise_date":"2024-06-10","expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":300},"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720974,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35064,"derivative":{"exercise_price":2.98,"exercise_date":"2023-06-12","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720973,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":132786,"derivative":{"exercise_price":2.84,"exercise_date":"2026-06-08","expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720972,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":33549,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":124714,"derivative":{"exercise_price":2.99,"exercise_date":"2024-06-10","expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":33549},"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720971,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":32173,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":35764,"derivative":{"exercise_price":2.98,"exercise_date":"2023-06-12","expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":32173},"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720970,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":9,"value":9000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720969,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":300,"price":2.99,"value":897.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720968,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":700,"price":2.98,"value":2086.0,"ownership":{"direct":true},"balance_after":700,"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720967,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":95722,"price":9.0075,"value":862215.915,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 95,722 shares sold in the price range of $9.00 to $9.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the \"Issuer\") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720966,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.84,"value":85200.0,"ownership":{"direct":true},"balance_after":95722,"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720965,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":33549,"price":2.99,"value":100311.51,"ownership":{"direct":true},"balance_after":65722,"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":720964,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T21:04:34.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":32173,"price":2.98,"value":95875.54,"ownership":{"direct":true},"balance_after":32173,"source":{"system":"sec-edgar","filing":"0001849739-26-000011","document":"wk-form4_1782939871.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000011/wk-form4_1782939871.xml","form_type":"4"}},{"id":725467,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-27T01:00:07.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":7.8763,"value":196907.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.875 to $7.885 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the \"Issuer\") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2802788,"source":{"system":"sec-edgar","filing":"0001647994-26-000011","document":"wk-form4_1782522004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000011/wk-form4_1782522004.xml","form_type":"4"}},{"id":742973,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":39629,"kind":"person","name":"BLASZYK MICHAEL D","position":1,"cik":"0001371407","reported_name":"BLASZYK MICHAEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T00:11:51.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":65600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders."}],"balance_after":65600,"derivative":{"exercise_price":7.25,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":65600},"source":{"system":"sec-edgar","filing":"0001371407-26-000003","document":"wk-form4_1781136707.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000137140726000003/wk-form4_1781136707.xml","form_type":"4"}},{"id":742972,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T00:11:44.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":65600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders."}],"balance_after":65600,"derivative":{"exercise_price":7.25,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":65600},"source":{"system":"sec-edgar","filing":"0001364846-26-000003","document":"wk-form4_1781136701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000136484626000003/wk-form4_1781136701.xml","form_type":"4"}},{"id":742971,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":29041,"kind":"person","name":"MAXWELL LINDA","position":1,"cik":"0001822674","reported_name":"MAXWELL LINDA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T00:11:36.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":65600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders."}],"balance_after":65600,"derivative":{"exercise_price":7.25,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":65600},"source":{"system":"sec-edgar","filing":"0001822674-26-000003","document":"wk-form4_1781136692.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000182267426000003/wk-form4_1781136692.xml","form_type":"4"}},{"id":742970,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":39627,"kind":"person","name":"Clark Wesley","position":1,"cik":"0001349193","reported_name":"Clark Wesley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T00:11:27.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":65600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders."}],"balance_after":65600,"derivative":{"exercise_price":7.25,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":65600},"source":{"system":"sec-edgar","filing":"0001349193-26-000003","document":"wk-form4_1781136683.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000134919326000003/wk-form4_1781136683.xml","form_type":"4"}},{"id":742969,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32092,"kind":"person","name":"Cohen Cheryl","position":1,"cik":"0001529371","reported_name":"Cohen Cheryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T00:11:18.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":65600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders."}],"balance_after":65600,"derivative":{"exercise_price":7.25,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":65600},"source":{"system":"sec-edgar","filing":"0001529371-26-000003","document":"wk-form4_1781136674.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000152937126000003/wk-form4_1781136674.xml","form_type":"4"}},{"id":742966,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T00:11:10.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":65600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders."}],"balance_after":65600,"derivative":{"exercise_price":7.25,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":65600},"source":{"system":"sec-edgar","filing":"0001849739-26-000007","document":"wk-form4_1781136666.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000007/wk-form4_1781136666.xml","form_type":"4"}},{"id":747916,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T21:29:40.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":23033,"price":7.1769,"value":165305.5377,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 23,033 shares sold in the price range of $7.125 to $7.225 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the \"Issuer\") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2827788,"source":{"system":"sec-edgar","filing":"0001647994-26-000008","document":"wk-form4_1780694977.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000008/wk-form4_1780694977.xml","form_type":"4"}},{"id":819288,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Second Amended and Restated Convertible Promissory Note","published_at":"2026-04-03T00:08:43.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":false,"price":0,"reported_value":25000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Nant Capital has the right at any time after December 10, 2024 and on or before December 31, 2027 to convert all or a portion of the outstanding principal amount of this Second Amended and Restated Promissory Note, as amended January 23, 2026, into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $5.427. On March 31, 2026, Nant Capital delivered notice to the Issuer electing to convert outstanding principal in the amount of $25,000,000 into 4,606,596 shares of the Issuer's common stock."},{"field":"underlyingValue","element":"underlyingSecurityValue","label":"F9","text":"Nant Capital has the right at any time after December 10, 2024 and on or before December 31, 2027 to convert all or a portion of the outstanding principal amount of this Second Amended and Restated Promissory Note, as amended January 23, 2026, into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $5.427. On March 31, 2026, Nant Capital delivered notice to the Issuer electing to convert outstanding principal in the amount of $25,000,000 into 4,606,596 shares of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person."}],"derivative":{"exercise_price":5.427,"exercise_date":"2024-12-10","expiration_date":"2027-12-31","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001189020-26-000008","document":"wk-form4_1775174919.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000008/wk-form4_1775174919.xml","form_type":"4"}},{"id":819287,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T00:08:43.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":true,"shares":4606596,"price":5.427,"value":24999996.492,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person."}],"balance_after":251018873,"source":{"system":"sec-edgar","filing":"0001189020-26-000008","document":"wk-form4_1775174919.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000008/wk-form4_1775174919.xml","form_type":"4"}},{"id":879636,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-27T01:12:26.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":75000,"price":12.0105,"value":900787.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $12.00 to $12.025 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the \"Issuer\") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2850821,"source":{"system":"sec-edgar","filing":"0001647994-26-000006","document":"wk-form4_1772154743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000006/wk-form4_1772154743.xml","form_type":"4"}},{"id":884468,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-25T01:05:58.000Z","date":"2026-02-23","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders."}],"balance_after":67937,"derivative":{"exercise_price":2.98,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001849739-26-000004","document":"wk-form4_1771981555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000004/wk-form4_1771981555.xml","form_type":"4"}},{"id":884467,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:05:58.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":10,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001849739-26-000004","document":"wk-form4_1771981555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000004/wk-form4_1771981555.xml","form_type":"4"}},{"id":884466,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:05:58.000Z","date":"2026-02-23","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":2.98,"value":74500.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001849739-26-000004","document":"wk-form4_1771981555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000004/wk-form4_1771981555.xml","form_type":"4"}},{"id":884465,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-25T01:05:12.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":false,"shares":40650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":40651,"derivative":{"underlying":"Common Stock","underlying_shares":40650},"source":{"system":"sec-edgar","filing":"0001848899-26-000005","document":"wk-form4_1771981509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000005/wk-form4_1771981509.xml","form_type":"4"}},{"id":884464,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T01:05:12.000Z","date":"2026-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":20682,"price":8.7,"value":179933.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":300143,"source":{"system":"sec-edgar","filing":"0001848899-26-000005","document":"wk-form4_1771981509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000005/wk-form4_1771981509.xml","form_type":"4"}},{"id":884463,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T01:05:12.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":true,"shares":40650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":320825,"source":{"system":"sec-edgar","filing":"0001848899-26-000005","document":"wk-form4_1771981509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000005/wk-form4_1771981509.xml","form_type":"4"}},{"id":884462,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-02-25T01:05:07.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":false,"shares":114329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":114329,"derivative":{"underlying":"Common Stock","underlying_shares":114329},"source":{"system":"sec-edgar","filing":"0001189020-26-000006","document":"wk-form4_1771981503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000006/wk-form4_1771981503.xml","form_type":"4"}},{"id":884461,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:05:07.000Z","date":"2026-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":58170,"price":8.7,"value":506079.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":29757911,"source":{"system":"sec-edgar","filing":"0001189020-26-000006","document":"wk-form4_1771981503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000006/wk-form4_1771981503.xml","form_type":"4"}},{"id":884460,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:05:07.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":true,"shares":114329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":29816081,"source":{"system":"sec-edgar","filing":"0001189020-26-000006","document":"wk-form4_1771981503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000006/wk-form4_1771981503.xml","form_type":"4"}},{"id":884459,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64916,"kind":"person","name":"LAUER REGAN J","position":1,"cik":"0001200637","reported_name":"LAUER REGAN J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-25T01:05:00.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":false,"shares":4065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":4065,"derivative":{"underlying":"Common Stock","underlying_shares":4065},"source":{"system":"sec-edgar","filing":"0001200637-26-000004","document":"wk-form4_1771981498.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120063726000004/wk-form4_1771981498.xml","form_type":"4"}},{"id":884458,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64916,"kind":"person","name":"LAUER REGAN J","position":1,"cik":"0001200637","reported_name":"LAUER REGAN J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-25T01:05:00.000Z","date":"2026-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":1673,"price":8.7,"value":14555.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":115875,"source":{"system":"sec-edgar","filing":"0001200637-26-000004","document":"wk-form4_1771981498.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120063726000004/wk-form4_1771981498.xml","form_type":"4"}},{"id":884457,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64916,"kind":"person","name":"LAUER REGAN J","position":1,"cik":"0001200637","reported_name":"LAUER REGAN J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-25T01:05:00.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":true,"shares":4065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":117548,"source":{"system":"sec-edgar","filing":"0001200637-26-000004","document":"wk-form4_1771981498.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120063726000004/wk-form4_1771981498.xml","form_type":"4"}},{"id":884453,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Restricted Stock Units","published_at":"2026-02-25T01:04:54.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":false,"shares":152439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":152439,"derivative":{"underlying":"Common Stock","underlying_shares":152439},"source":{"system":"sec-edgar","filing":"0001830328-26-000005","document":"wk-form4_1771981491.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000183032826000005/wk-form4_1771981491.xml","form_type":"4"}},{"id":884452,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-25T01:04:54.000Z","date":"2026-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":77560,"price":8.7,"value":674772.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":560344,"source":{"system":"sec-edgar","filing":"0001830328-26-000005","document":"wk-form4_1771981491.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000183032826000005/wk-form4_1771981491.xml","form_type":"4"}},{"id":884451,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-25T01:04:54.000Z","date":"2026-02-22","kind":"exercise","planned":false,"acquired":true,"shares":152439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":637904,"source":{"system":"sec-edgar","filing":"0001830328-26-000005","document":"wk-form4_1771981491.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000183032826000005/wk-form4_1771981491.xml","form_type":"4"}},{"id":884786,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-02-25T01:03:46.000Z","date":"2026-02-22","kind":"exercise","planned":true,"acquired":false,"shares":15243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":15245,"derivative":{"underlying":"Common Stock","underlying_shares":15243},"source":{"system":"sec-edgar","filing":"0001647994-26-000004","document":"wk-form4_1771981423.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000004/wk-form4_1771981423.xml","form_type":"4"}},{"id":884785,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:03:46.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":165000,"price":10.2491,"value":1691101.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 165,000 shares sold in the price range of $9.89 to $10.635 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":2925821,"source":{"system":"sec-edgar","filing":"0001647994-26-000004","document":"wk-form4_1771981423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000004/wk-form4_1771981423.xml","form_type":"4"}},{"id":884784,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:03:46.000Z","date":"2026-02-22","kind":"tax_withholding","planned":true,"acquired":false,"shares":6026,"price":8.7,"value":52426.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":3090821,"source":{"system":"sec-edgar","filing":"0001647994-26-000004","document":"wk-form4_1771981423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000004/wk-form4_1771981423.xml","form_type":"4"}},{"id":884783,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:03:46.000Z","date":"2026-02-22","kind":"exercise","planned":true,"acquired":true,"shares":15243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":3096847,"source":{"system":"sec-edgar","filing":"0001647994-26-000004","document":"wk-form4_1771981423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000004/wk-form4_1771981423.xml","form_type":"4"}},{"id":884782,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-25T01:03:46.000Z","date":"2026-02-20","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":9.25,"value":92500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024."}],"balance_after":3081604,"source":{"system":"sec-edgar","filing":"0001647994-26-000004","document":"wk-form4_1771981423.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000004/wk-form4_1771981423.xml","form_type":"4"}},{"id":907423,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-02-13T02:29:23.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":false,"shares":274122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."}],"balance_after":548246,"derivative":{"underlying":"Common Stock","underlying_shares":274122},"source":{"system":"sec-edgar","filing":"0001189020-26-000003","document":"wk-form4_1770949759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000003/wk-form4_1770949759.xml","form_type":"4"}},{"id":907422,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T02:29:23.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":118560,"price":6.93,"value":821620.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":29701752,"source":{"system":"sec-edgar","filing":"0001189020-26-000003","document":"wk-form4_1770949759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000003/wk-form4_1770949759.xml","form_type":"4"}},{"id":907421,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":3,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":4,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T02:29:23.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":true,"shares":274122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":29820312,"source":{"system":"sec-edgar","filing":"0001189020-26-000003","document":"wk-form4_1770949759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000118902026000003/wk-form4_1770949759.xml","form_type":"4"}},{"id":907426,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-13T01:50:40.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":false,"shares":82236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."}],"balance_after":164474,"derivative":{"underlying":"Common Stock","underlying_shares":82236},"source":{"system":"sec-edgar","filing":"0001848899-26-000003","document":"wk-form4_1770947437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000003/wk-form4_1770947437.xml","form_type":"4"}},{"id":907425,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-13T01:50:40.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":42643,"price":6.93,"value":295515.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":280175,"source":{"system":"sec-edgar","filing":"0001848899-26-000003","document":"wk-form4_1770947437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000003/wk-form4_1770947437.xml","form_type":"4"}},{"id":907424,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-13T01:50:40.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":true,"shares":82236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":322818,"source":{"system":"sec-edgar","filing":"0001848899-26-000003","document":"wk-form4_1770947437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000003/wk-form4_1770947437.xml","form_type":"4"}},{"id":907417,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64916,"kind":"person","name":"LAUER REGAN J","position":1,"cik":"0001200637","reported_name":"LAUER REGAN J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-13T01:50:34.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":false,"shares":5482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."}],"balance_after":10965,"derivative":{"underlying":"Common Stock","underlying_shares":5482},"source":{"system":"sec-edgar","filing":"0001200637-26-000002","document":"wk-form4_1770947431.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120063726000002/wk-form4_1770947431.xml","form_type":"4"}},{"id":907416,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64916,"kind":"person","name":"LAUER REGAN J","position":1,"cik":"0001200637","reported_name":"LAUER REGAN J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-13T01:50:34.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":2257,"price":6.93,"value":15641.01,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":113483,"source":{"system":"sec-edgar","filing":"0001200637-26-000002","document":"wk-form4_1770947431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120063726000002/wk-form4_1770947431.xml","form_type":"4"}},{"id":907415,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64916,"kind":"person","name":"LAUER REGAN J","position":1,"cik":"0001200637","reported_name":"LAUER REGAN J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-02-13T01:50:34.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":true,"shares":5482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":115740,"source":{"system":"sec-edgar","filing":"0001200637-26-000002","document":"wk-form4_1770947431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000120063726000002/wk-form4_1770947431.xml","form_type":"4"}},{"id":907420,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Restricted Stock Units","published_at":"2026-02-13T01:50:26.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":false,"shares":274122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025."}],"balance_after":548246,"derivative":{"underlying":"Common Stock","underlying_shares":274122},"source":{"system":"sec-edgar","filing":"0001830328-26-000003","document":"wk-form4_1770947424.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000183032826000003/wk-form4_1770947424.xml","form_type":"4"}},{"id":907419,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-13T01:50:26.000Z","date":"2026-02-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":140048,"price":6.93,"value":970532.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld."}],"balance_after":485465,"source":{"system":"sec-edgar","filing":"0001830328-26-000003","document":"wk-form4_1770947424.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000183032826000003/wk-form4_1770947424.xml","form_type":"4"}},{"id":907418,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-13T01:50:26.000Z","date":"2026-02-10","kind":"exercise","planned":false,"acquired":true,"shares":274122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":625513,"source":{"system":"sec-edgar","filing":"0001830328-26-000003","document":"wk-form4_1770947424.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000183032826000003/wk-form4_1770947424.xml","form_type":"4"}},{"id":934205,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T01:34:45.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":75000,"price":7.8791,"value":590932.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $7.87 to $7.8950 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":3091604,"source":{"system":"sec-edgar","filing":"0001647994-26-000002","document":"wk-form4_1769045681.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000002/wk-form4_1769045681.xml","form_type":"4"}},{"id":934204,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T01:34:45.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":76967,"price":6.54,"value":503364.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024."}],"balance_after":3166604,"source":{"system":"sec-edgar","filing":"0001647994-26-000002","document":"wk-form4_1769045681.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000164799426000002/wk-form4_1769045681.xml","form_type":"4"}},{"id":934119,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-22T01:33:48.000Z","date":"2026-01-20","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders."}],"balance_after":92937,"derivative":{"exercise_price":2.98,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001849739-26-000002","document":"wk-form4_1769045624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000002/wk-form4_1769045624.xml","form_type":"4"}},{"id":934118,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-22T01:33:48.000Z","date":"2026-01-16","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders."}],"balance_after":117937,"derivative":{"exercise_price":2.98,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001849739-26-000002","document":"wk-form4_1769045624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000002/wk-form4_1769045624.xml","form_type":"4"}},{"id":934117,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T01:33:48.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":7.506,"value":187650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.50 to $7.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001849739-26-000002","document":"wk-form4_1769045624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000002/wk-form4_1769045624.xml","form_type":"4"}},{"id":934116,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T01:33:48.000Z","date":"2026-01-20","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":2.98,"value":74500.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001849739-26-000002","document":"wk-form4_1769045624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000002/wk-form4_1769045624.xml","form_type":"4"}},{"id":934115,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T01:33:48.000Z","date":"2026-01-16","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":5,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001849739-26-000002","document":"wk-form4_1769045624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000002/wk-form4_1769045624.xml","form_type":"4"}},{"id":934114,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-22T01:33:48.000Z","date":"2026-01-16","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":2.98,"value":149000.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001849739-26-000002","document":"wk-form4_1769045624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184973926000002/wk-form4_1769045624.xml","form_type":"4"}},{"id":950828,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T23:11:44.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":30397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."}],"balance_after":45602,"derivative":{"underlying":"Common Stock","underlying_shares":30397},"source":{"system":"sec-edgar","filing":"0001848899-26-000001","document":"wk-form4_1767654699.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000001/wk-form4_1767654699.xml","form_type":"4"}},{"id":950827,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T23:11:44.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":15435,"price":1.98,"value":30561.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":240582,"source":{"system":"sec-edgar","filing":"0001848899-26-000001","document":"wk-form4_1767654699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000001/wk-form4_1767654699.xml","form_type":"4"}},{"id":950826,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T23:11:44.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":30397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."}],"balance_after":256017,"source":{"system":"sec-edgar","filing":"0001848899-26-000001","document":"wk-form4_1767654699.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000184889926000001/wk-form4_1767654699.xml","form_type":"4"}},{"id":950825,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T23:10:33.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":false,"shares":34483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026."}],"balance_after":51731,"derivative":{"underlying":"Common Stock","underlying_shares":34483},"source":{"system":"sec-edgar","filing":"0001830328-26-000001","document":"wk-form4_1767654629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000183032826000001/wk-form4_1767654629.xml","form_type":"4"}},{"id":950824,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-01-05T23:10:33.000Z","date":"2025-12-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":17510,"price":1.98,"value":34669.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":351391,"source":{"system":"sec-edgar","filing":"0001830328-26-000001","document":"wk-form4_1767654629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000183032826000001/wk-form4_1767654629.xml","form_type":"4"}},{"id":950823,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-01-05T23:10:33.000Z","date":"2025-12-31","kind":"exercise","planned":false,"acquired":true,"shares":34483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. common stock."}],"balance_after":368901,"source":{"system":"sec-edgar","filing":"0001830328-26-000001","document":"wk-form4_1767654629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000183032826000001/wk-form4_1767654629.xml","form_type":"4"}},{"id":967363,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":39628,"kind":"person","name":"Wendel Bruce","position":1,"cik":"0001364846","reported_name":"Wendel Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-16T22:55:49.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":146020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2025 Equity Incentive Plan) through each applicable vesting date, 48,673 of the shares subject to the award will vest on December 12, 2026, 48,673 of the shares subject to the award will vest on December 12, 2027 and 48,674 of the shares subject to the award will vest on December 12, 2028, such that the award will be fully vested on December 12, 2028; provided that, notwithstanding the foregoing, any unvested shares subject to the award will fully vest immediately prior to a Change in Control (as defined in the 2025 Equity Incentive Plan), subject to the reporting person continuing to be a Service Provider through the date of such Change in Control."}],"balance_after":146020,"derivative":{"exercise_price":2.36,"expiration_date":"2035-12-12","underlying":"Common Stock","underlying_shares":146020},"source":{"system":"sec-edgar","filing":"0001364846-25-000007","document":"wk-form4_1765925747.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000136484625000007/wk-form4_1765925747.xml","form_type":"4"}},{"id":1104895,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32090,"kind":"person","name":"Selecky Christobel","position":1,"cik":"0001849739","reported_name":"Selecky Christobel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T22:34:57.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":162786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders."}],"balance_after":162786,"derivative":{"exercise_price":2.84,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":162786},"source":{"system":"sec-edgar","filing":"0001326110-25-000094","document":"wk-form4_1750458891.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000094/wk-form4_1750458891.xml","form_type":"4"}},{"id":1104894,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":32092,"kind":"person","name":"Cohen Cheryl","position":1,"cik":"0001529371","reported_name":"Cohen Cheryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T22:34:47.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":162786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next  annual meeting of stockholders."}],"balance_after":162786,"derivative":{"exercise_price":2.84,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":162786},"source":{"system":"sec-edgar","filing":"0001326110-25-000093","document":"wk-form4_1750458881.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000093/wk-form4_1750458881.xml","form_type":"4"}},{"id":1104893,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":39629,"kind":"person","name":"BLASZYK MICHAEL D","position":1,"cik":"0001371407","reported_name":"BLASZYK MICHAEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T22:34:38.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":162786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders."}],"balance_after":162786,"derivative":{"exercise_price":2.84,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":162786},"source":{"system":"sec-edgar","filing":"0001326110-25-000092","document":"wk-form4_1750458872.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000092/wk-form4_1750458872.xml","form_type":"4"}},{"id":1104892,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":29041,"kind":"person","name":"MAXWELL LINDA","position":1,"cik":"0001822674","reported_name":"MAXWELL LINDA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T22:34:29.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":162786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders."}],"balance_after":162786,"derivative":{"exercise_price":2.84,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":162786},"source":{"system":"sec-edgar","filing":"0001326110-25-000091","document":"wk-form4_1750458862.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000091/wk-form4_1750458862.xml","form_type":"4"}},{"id":1104891,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":39627,"kind":"person","name":"Clark Wesley","position":1,"cik":"0001349193","reported_name":"Clark Wesley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-20T22:34:19.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":162786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders."}],"balance_after":162786,"derivative":{"exercise_price":2.84,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":162786},"source":{"system":"sec-edgar","filing":"0001326110-25-000090","document":"wk-form4_1750458853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000090/wk-form4_1750458853.xml","form_type":"4"}},{"id":1245776,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64916,"kind":"person","name":"LAUER REGAN J","position":1,"cik":"0001200637","reported_name":"LAUER REGAN J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-26T02:11:45.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":false,"shares":4065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":8130,"derivative":{"underlying":"Common Stock","underlying_shares":4065},"source":{"system":"sec-edgar","filing":"0001326110-25-000024","document":"wk-form4_1740535899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000024/wk-form4_1740535899.xml","form_type":"4"}},{"id":1245775,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64916,"kind":"person","name":"LAUER REGAN J","position":1,"cik":"0001200637","reported_name":"LAUER REGAN J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-26T02:11:45.000Z","date":"2025-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":1669,"price":3.42,"value":5707.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":110258,"source":{"system":"sec-edgar","filing":"0001326110-25-000024","document":"wk-form4_1740535899.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000024/wk-form4_1740535899.xml","form_type":"4"}},{"id":1245774,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64916,"kind":"person","name":"LAUER REGAN J","position":1,"cik":"0001200637","reported_name":"LAUER REGAN J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-26T02:11:45.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":true,"shares":4065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":111927,"source":{"system":"sec-edgar","filing":"0001326110-25-000024","document":"wk-form4_1740535899.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000024/wk-form4_1740535899.xml","form_type":"4"}},{"id":1245773,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-02-26T02:11:37.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":false,"shares":114329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":228658,"derivative":{"underlying":"Common Stock","underlying_shares":114329},"source":{"system":"sec-edgar","filing":"0001326110-25-000023","document":"wk-form4_1740535889.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000023/wk-form4_1740535889.xml","form_type":"4"}},{"id":1245772,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-26T02:11:37.000Z","date":"2025-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":42071,"price":3.42,"value":143882.82,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":29546190,"source":{"system":"sec-edgar","filing":"0001326110-25-000023","document":"wk-form4_1740535889.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000023/wk-form4_1740535889.xml","form_type":"4"}},{"id":1245771,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":54234,"kind":"person","name":"SOON-SHIONG PATRICK","position":1,"cik":"0001189020","reported_name":"SOON-SHIONG PATRICK","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See remarks"}},{"id":54235,"kind":"organization","name":"CALIFORNIA CAPITAL EQUITY, LLC","position":2,"cik":"0001517764","reported_name":"CALIFORNIA CAPITAL EQUITY, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54237,"kind":"organization","name":"MP 13 Ventures, LLC","position":3,"cik":"0001629186","reported_name":"MP 13 Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54236,"kind":"organization","name":"Cambridge Equities, LP","position":4,"cik":"0001629222","reported_name":"Cambridge Equities, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":54238,"kind":"organization","name":"Nant Capital, LLC","position":5,"cik":"0001675758","reported_name":"Nant Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-26T02:11:37.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":true,"shares":114329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":29588261,"source":{"system":"sec-edgar","filing":"0001326110-25-000023","document":"wk-form4_1740535889.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000023/wk-form4_1740535889.xml","form_type":"4"}},{"id":1245770,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-26T02:11:26.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":false,"shares":40650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":81301,"derivative":{"underlying":"Common Stock","underlying_shares":40650},"source":{"system":"sec-edgar","filing":"0001326110-25-000022","document":"wk-form4_1740535880.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000022/wk-form4_1740535880.xml","form_type":"4"}},{"id":1245769,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-26T02:11:26.000Z","date":"2025-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":15860,"price":3.42,"value":54241.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":225620,"source":{"system":"sec-edgar","filing":"0001326110-25-000022","document":"wk-form4_1740535880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000022/wk-form4_1740535880.xml","form_type":"4"}},{"id":1245768,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64917,"kind":"person","name":"Sachs David C.","position":1,"cik":"0001848899","reported_name":"Sachs David C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-26T02:11:26.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":true,"shares":40650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":241480,"source":{"system":"sec-edgar","filing":"0001326110-25-000022","document":"wk-form4_1740535880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000022/wk-form4_1740535880.xml","form_type":"4"}},{"id":1245766,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Restricted Stock Units","published_at":"2025-02-26T02:11:15.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":false,"shares":152439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":304878,"derivative":{"underlying":"Common Stock","underlying_shares":152439},"source":{"system":"sec-edgar","filing":"0001326110-25-000021","document":"wk-form4_1740535870.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000021/wk-form4_1740535870.xml","form_type":"4"}},{"id":1245765,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-26T02:11:15.000Z","date":"2025-02-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":78167,"price":3.42,"value":267331.14,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld."}],"balance_after":334418,"source":{"system":"sec-edgar","filing":"0001326110-25-000021","document":"wk-form4_1740535870.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000021/wk-form4_1740535870.xml","form_type":"4"}},{"id":1245764,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":64915,"kind":"person","name":"Adcock Richard","position":1,"cik":"0001830328","reported_name":"Adcock Richard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-26T02:11:15.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":true,"shares":152439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."}],"balance_after":412585,"source":{"system":"sec-edgar","filing":"0001326110-25-000021","document":"wk-form4_1740535870.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000021/wk-form4_1740535870.xml","form_type":"4"}},{"id":1246145,"issuer":{"id":3618,"kind":"organization","name":"ImmunityBio, Inc.","symbol":"IBRX"},"owners":[{"id":35137,"kind":"person","name":"Simon Barry J.","position":1,"cik":"0001647994","reported_name":"Simon Barry J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-02-26T02:11:06.000Z","date":"2025-02-22","kind":"exercise","planned":false,"acquired":false,"shares":15243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of ImmunityBio, Inc. (the \"Issuer\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024."}],"balance_after":30488,"derivative":{"underlying":"Common Stock","underlying_shares":15243},"source":{"system":"sec-edgar","filing":"0001326110-25-000020","document":"wk-form4_1740535859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1647994/000132611025000020/wk-form4_1740535859.xml","form_type":"4"}}],"next_cursor":"2025-02-26T02:11:06.000000Z,1246145"}